Changes in Cerebral Glucose Metabolism in Patients with Parkinson Disease with Dementia After Cholinesterase Inhibitor Therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Nuclear Medicine

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.108.054668PMID 18997034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [11C]PIB binding in Parkinson's disease dementia

  2008cited by this paper
• Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.

  2008cited by this paper
• Imaging beta-amyloid burden in aging and dementia.

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• Rivastigmine in Dementia Associated with Parkinson's Disease and Alzheimer's Disease: Similarities and Differences

  2007cited by this paper
• Cognitive dysfunction and dementia in Parkinson disease

  2007cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• DLB and PDD boundary issues

  2007cited by this paper
• Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia

  2006cited by this paper
• Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

  2006cited by this paper
• Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease

  2006cited by this paper
• Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD

  2006cited by this paper
• Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia

  2006cited by this paper
• Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB

  2006cited by this paper
• Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer’s disease: a double-blind cross-over trial

  2006cited by this paper
• Dementia in Parkinson disease

  2005cited by this paper
• Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism

  2005cited by this paper
• Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Visual perception in Parkinson disease dementia and dementia with Lewy bodies

  2004cited by this paper
• Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies

  2004cited by this paper
• Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease

  2004cited by this paper
• Rivastigmine for dementia associated with Parkinson's disease.

  2004cited by this paper
• Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

  2003cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Regional cerebral blood flow in Parkinson's disease with and without dementia

  2003cited by this paper
• Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

  2002cited by this paper
• Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

  2002cited by this paper
• Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

  2002cited by this paper
• Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

  2001cited by this paper
• Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment

  2001cited by this paper
• Risk of dementia in Parkinson’s disease

  2001cited by this paper
• Cholinergic dysfunction in diseases with Lewy bodies

  2000cited by this paper
• In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism

  2000cited by this paper
• Location of human face‐selective cortex with respect to retinotopic areas

  1999cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

  1985cited by this paper
• Dementia associated with Parkinson's disease: a genetic study.

  1980cited by this paper

• Novel insights into relationships between metabolic covariance patterns of FDG-PET data and clinical status in Parkinson's disease using partial least squares correlation analysis

  2025cites this paper
• Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases.

  2022cites this paper
• Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinson’s disease

  2022cites this paper
• Cingulate cortex in Parkinson's disease.

  2019cites this paper
• Combined 18F-fluorodeoxyglucose positron emission tomography and event-related potentials study of the cognitive impairment mechanisms in Parkinson's disease.

  2019cites this paper
• [Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson's disease].

  2017cites this paper
• PET imaging in neurology: Alzheimer's and Parkinson's diseases.

  2015cites this paper
• Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.

  2015cites this paper
• Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease

  2015cites this paper
• Molecular imaging as a guide for the treatment of central nervous system disorders

  2013cites this paper
• Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease

  2012cites this paper
• PET studies in Parkinson's disease motor and cognitive dysfunction.

  2012cites this paper
• [Imaging non motor signs in Parkinson's disease].

  2012cites this paper
• Psychiatry of Parkinson’s Disease

  2012cites this paper
• Imagerie des signes non moteurs dans la maladie de Parkinson

  2012cites this paper
• Parkinson’s Disease with Dementia

  2012cites this paper
• Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD).

  2011cites this paper
• Effect of proinflammatory activation on the neurosupportive functions of astrocytes

  2011cites this paper
• Imaging Approaches to Parkinson Disease

  2010cites this paper
• The Treatment of Cognitive Impairment Associated with Parkinson's Disease

  2010cites this paper
• Functional Imaging of Cognitive Impairment in Parkinson's Disease

  2010cites this paper
• Recent advances in PET imaging for evaluation of Parkinson’s disease

  2010cites this paper
• Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration—[18F]FDG‐PET

  2009cites this paper
• Recent imaging advances in the diagnosis and management of Parkinson’s disease

  2009cites this paper